- Clinicians developing therapeutic strategies using targeted therapy
- Patients who lack an effective standard-of-care therapy
- Patients resistant to conventional therapy
- Patients with an unusual clinical presentation
- Patients with relapses after prior therapies
- Clinicians who want to identify clinical trials
- Clinicians who want to obtain diagnostics and prognostics information of certain tumours with specific molecular markers Patients and Clinicians when a relapse occurs after prior therapies
- Small amount of tissue sample required
- Predicting response to therapy
- Identifying new therapeutic approaches
- Identifying clinical trial opportunities
- Confirming diagnosis
- Assessing prognosis
A: We have three offices in Asia, located in Singapore, Hong Kong and Malaysia. If you are a patient you can ask your clinician to request the test for you. If you are a clinician, you can submit your request here. Our staff will contact and then advice you.
A: Presently the test can only be ordered by a clinician who can submit the request here. If you are a patient considering the test for yourself, a loved one or someone you know, consult your clinician who will advise you.
A: The clinical report will enable clinicians to optimize cancer treatment for their patients by providing the following information:
- Patient’s genetic marker
- FDA-approved targeted therapies of potential benefit for the patient
- Investigational therapies of potential benefit with open clinical trials
- Therapies lacking benefit for the patient
- Clinical trials information (trial ID, title, phase, location and sponsor)
- Brief information and references on the patient’s genetic marker
- A curated gene list
- Test methods
- Test limitations
FETAL MATERNAL HEALTH
A: Embryos generated from an IVF cycle with extra whole chromosome(s) or missing chromosome(s) usually do not develop correctly. These embryos may not be successfully implanted, miscarry during a pregnancy or result in a baby born with birth defects. Our Pre-implantation Genetic Screening (PGS) uses the array comparative genomic hybridization (aCGH) technology to evaluate the total number of chromosomes in a single cell and determine any gain or loss of chromosomes to ensure a euploid embryo. If genetic defects exist within embryos, certain diseases or disorders may pass on from parent to child. Pre-implantation Genetic Diagnosis (PGD) can identify inherited genetic conditions like Thalassemia in embryos. Its main advantage is to identify genetically affected embryo before implantation.
A: NIPS for pregnant women will identify the most common chromosomal anomalies in a foetus as early as nine weeks after the successful implantation of the embryos generated during an IVF cycle. The technology has been validated globally, showing highly sensitive and specific detection of trisomy 21, trisomy 18, trisomy 13, monosomy X and now triploidy.
A: Fetal DNA Chip is a fast and accurate diagnostic test designed on a chip between Angsana Molecular Diagnostics and the Chinese University of Hong Kong which covers the 23 pairs of human chromosomes. It includes common micro-deletion and/or duplication syndromes, many of which would not be detected by conventional karyotype analysis. Fetal DNA chip can give a more comprehensive, higher resolution and earlier result than conventional karyotype analysis. It gives up to extra 15% diagnostic yield compared to conventional cytogenetic analysis.
A: Numerous health conditions can be inherited by the child from the parent(s). We offer pregnant women or anyone planning a pregnancy carrier screenings such as Fragile X Syndrome and Thalassemia to detect whether one or both parents carry genetic variations that may result in disease(s) in the child.